Bone marrow adipocytes induce cancer-associated fibroblasts and immune evasion, enhancing invasion and drug resistance.
adipocyte
bone marrow
bone metastasis
drug resistance
invasive front
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
revised:
06
03
2023
received:
28
12
2022
accepted:
07
03
2023
medline:
5
6
2023
pubmed:
15
3
2023
entrez:
14
3
2023
Statut:
ppublish
Résumé
Bone metastasis occurs frequently in cancer patients. Conventional therapies have limited therapeutic outcomes, and thus, exploring the mechanisms of cancer progression in bone metastasis is important to develop new effective therapies. In the bone microenvironment, adipocytes are the major stromal cells that interact with cancer cells during bone metastasis. However, the comprehensive functions of bone marrow adipocytes in cancer progression are not yet fully understood. To address this, we investigated the role of bone marrow adipocytes on cancer cells, by focusing on an invasive front that reflects the direct effects of stromal cells on cancer. In comprehensive histopathological and genetic analysis using bone metastasis specimens, we examined invasive fronts in bone metastasis and compared invasive fronts with adipocyte-rich bone marrow (adipo-BM) to those with hematopoietic cell-rich bone marrow (hemato-BM) as a normal counterpart of adipocytes. We found morphological complexity of the invasive front with adipo-BM was significantly higher than that with hemato-BM. Based on immunohistochemistry, the invasive front with adipo-BM comparatively had a significantly increased cancer-associated fibroblast (CAF) marker-positive area and lower density of CD8
Identifiants
pubmed: 36916999
doi: 10.1111/cas.15786
pmc: PMC10236619
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2674-2688Subventions
Organisme : Foundation for Promotion of Cancer Research
Organisme : Japan Society for the Promotion of Science
ID : JP20K09422
Organisme : Takeda Medical Research Foundation
Informations de copyright
© 2023 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Clin Cancer Res. 2017 Aug 15;23(16):4556-4568
pubmed: 28468947
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
JAMA. 2017 Jan 3;317(1):48-58
pubmed: 28030702
Surgeon. 2017 Apr;15(2):76-82
pubmed: 27498412
J Bone Oncol. 2020 Oct 08;25:100325
pubmed: 33101888
Implant Dent. 2009 Apr;18(2):132-41
pubmed: 19359864
Cancer Rep (Hoboken). 2023 Jan;6(1):e1647
pubmed: 35691615
J Clin Invest. 2020 Sep 1;130(9):4704-4709
pubmed: 32749238
Cancer Discov. 2022 Feb;12(2):356-371
pubmed: 34544752
Pathol Oncol Res. 2004;10(3):149-53
pubmed: 15448750
Br J Cancer. 2009 Oct 20;101(8):1382-92
pubmed: 19755986
Clin Cancer Res. 2008 Aug 15;14(16):5013-21
pubmed: 18698019
Lancet. 2011 Mar 5;377(9768):813-22
pubmed: 21353695
Cancer Sci. 2020 Oct;111(10):3468-3477
pubmed: 33044028
Eur Urol. 1993;24(2):286-90
pubmed: 8375452
N Engl J Med. 2004 Apr 15;350(16):1655-64
pubmed: 15084698
PLoS Med. 2016 Dec 27;13(12):e1002201
pubmed: 28027327
Nature. 2017 Aug 17;548(7667):297-303
pubmed: 28783718
Cancer Rep (Hoboken). 2020 Feb;3(1):e1156
pubmed: 32632400
Sci Rep. 2016 Nov 02;6:36149
pubmed: 27805003
Cancer Sci. 2023 Jan;114(1):16-24
pubmed: 36197901
Front Endocrinol (Lausanne). 2020 Oct 14;11:567844
pubmed: 33162934
Vet Immunol Immunopathol. 2017 Sep;191:44-50
pubmed: 28895865
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Int J Cancer. 2021 Dec 1;149(11):1961-1972
pubmed: 34469585
Blood. 1999 Jun 1;93(11):3610-6
pubmed: 10339465
J Clin Oncol. 2018 Jun 1;36(16):1579-1587
pubmed: 29590008
J Pers Med. 2022 Apr 19;12(5):
pubmed: 35629078
Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2017 Mar 1;38(1):63-73
pubmed: 28593886
Medicina (Kaunas). 2019 Dec 30;56(1):
pubmed: 31906017
Oncogene. 2021 Jun;40(23):3989-4003
pubmed: 33994542
EBioMedicine. 2020 Jul;57:102860
pubmed: 32652320
Surgeon. 2022 Oct;20(5):328-333
pubmed: 34563452
Int J Cancer. 2015 Aug 15;137(4):784-96
pubmed: 25648219
Cancers (Basel). 2020 Dec 16;12(12):
pubmed: 33339340
Hepatology. 2022 Oct;76(4):967-981
pubmed: 35108400
Front Cell Dev Biol. 2020 Apr 28;8:282
pubmed: 32411704
PLoS One. 2014 May 06;9(5):e96801
pubmed: 24802416
Annu Int Conf IEEE Eng Med Biol Soc. 2013;2013:5445-8
pubmed: 24110968
Ageing Res Rev. 2021 May;67:101259
pubmed: 33515751
Int J Mol Sci. 2019 Jan 11;20(2):
pubmed: 30641973
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Cancer Sci. 2023 Jun;114(6):2674-2688
pubmed: 36916999
Horm Mol Biol Clin Investig. 2015 Jan;21(1):43-56
pubmed: 25781551
Lancet. 2021 Sep 11;398(10304):1002-1014
pubmed: 34509219
Cells. 2019 Sep 05;8(9):
pubmed: 31492019
J Exp Med. 1999 Feb 1;189(3):447-50
pubmed: 9927506
Asian Pac J Cancer Prev. 2013;14(9):5165-9
pubmed: 24175794
J Nippon Med Sch. 2019;86(3):159-164
pubmed: 31292327
J Bone Oncol. 2018 Nov 06;15:004-4
pubmed: 30937279
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
J Clin Pathol. 2004 Mar;57(3):250-5
pubmed: 14990594
Int Orthop. 2020 Dec;44(12):2787-2805
pubmed: 33037446
Cell. 2020 Apr 16;181(2):486-486.e1
pubmed: 32302576
Mol Oncol. 2016 Oct 7;11(1):62-78
pubmed: 28017284
Nat Cancer. 2020 Apr;1(4):452-468
pubmed: 35121966
Bone. 2022 May;158:115783
pubmed: 33276151
Cancer Sci. 2017 Jul;108(7):1293-1302
pubmed: 28417530
J Clin Oncol. 2022 Feb 20;40(6):671-680
pubmed: 34985925
Eur J Pharmacol. 2022 Aug 5;928:175087
pubmed: 35679891
Front Endocrinol (Lausanne). 2019 Feb 26;10:114
pubmed: 30863366
Cancer Res. 2006 Dec 1;66(23):11271-8
pubmed: 17145872
BMC Res Notes. 2019 Mar 13;12(1):133
pubmed: 30867032
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Clin Cancer Res. 2013 Nov 15;19(22):6074-83
pubmed: 23958744
Nat Rev Clin Oncol. 2021 Dec;18(12):792-804
pubmed: 34489603
Curr Osteoporos Rep. 2018 Oct;16(5):596-602
pubmed: 30128835
Ann Oncol. 1995 Oct;6(8):817-25
pubmed: 8589021
N Engl J Med. 2009 Aug 13;361(7):653-63
pubmed: 19675329
Cancer. 1997 Oct 15;80(8 Suppl):1527-701
pubmed: 9377495
Cancer Res. 2022 Sep 16;82(18):3291-3306
pubmed: 35862581
Cancer Cell. 2005 May;7(5):485-96
pubmed: 15894268
Medicine (Baltimore). 2019 May;98(18):e15164
pubmed: 31045759
Nat Rev Cancer. 2016 Aug 23;16(9):582-98
pubmed: 27550820
Cancer Res. 2016 Oct 1;76(19):5832-5844
pubmed: 27569215
Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6243s-6249s
pubmed: 17062708
Clin Cancer Res. 2020 Jul 1;26(13):3230-3238
pubmed: 32220891
Int J Mol Sci. 2021 Feb 22;22(4):
pubmed: 33671547
Int J Mol Sci. 2022 Jun 20;23(12):
pubmed: 35743275
Mol Cancer Res. 2012 Nov;10(11):1403-18
pubmed: 23024188
Nat Rev Cancer. 2020 Apr;20(4):218-232
pubmed: 32024970
Transl Oncol. 2020 Feb;13(2):308-320
pubmed: 31877463
Exp Biol Med (Maywood). 2021 Aug;246(16):1810-1815
pubmed: 34229470
Cancer Sci. 2021 Mar;112(3):1251-1261
pubmed: 33393151
Semin Oncol. 2014 Apr;41(2):281-95
pubmed: 24787299
Cancer Res. 2022 Aug 16;82(16):2904-2917
pubmed: 35749591
N Engl J Med. 2021 Apr 1;384(13):1191-1203
pubmed: 33789008
Head Neck. 2009 Oct;31(10):1346-53
pubmed: 19373786
Cells. 2019 Aug 08;8(8):
pubmed: 31398937
Cancer Res. 2005 Jul 15;65(14):6054-62
pubmed: 16024605
Prostate. 2006 Nov 1;66(15):1573-84
pubmed: 16927388
Cancer. 1997 Oct 15;80(8 Suppl):1546-56
pubmed: 9362421
Br J Cancer. 2014 May 13;110(10):2551-9
pubmed: 24675384
Cancer Sci. 2008 Feb;99(2):316-23
pubmed: 18271931
Front Immunol. 2022 May 30;13:867516
pubmed: 35707534
Neoplasia. 2021 Jan;23(1):102-111
pubmed: 33296752
ESMO Open. 2018 Nov 1;3(7):e000452
pubmed: 30425850
Cancer Cell. 2018 Jan 8;33(1):125-136.e3
pubmed: 29316426
FASEB J. 2022 Nov;36(11):e22597
pubmed: 36197688
Front Biosci (Landmark Ed). 2010 Jan 01;15(1):151-65
pubmed: 20036812
Matrix Biol. 2011 Apr;30(3):225-33
pubmed: 21349332
Clin Exp Metastasis. 2020 Dec;37(6):693-702
pubmed: 33099723
Mol Med Rep. 2021 Dec;24(6):
pubmed: 34676881
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123
Ann Oncol. 2017 Jul 01;28(7):1532-1539
pubmed: 28407039
Medicine (Baltimore). 2019 Nov;98(45):e17832
pubmed: 31702638
J Clin Oncol. 2010 Mar 20;28(9):e140; author reply e141-2
pubmed: 20159803
Cancer Res. 2013 Dec 1;73(23):6843-7
pubmed: 24265274
Onco Targets Ther. 2017 Oct 27;10:5219-5228
pubmed: 29138574
Curr Treat Options Oncol. 2005 Mar;6(2):161-71
pubmed: 15717997